15 Best S&P 500 Dividend Stocks to Buy in 2026
Dividend stocks have often provided stability when markets get difficult.
Merck & Co. Inc. (MRK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bourgeon Capital John Zaro | 164,356 | $17,300,368 | -2% | 2.8% |
| 2. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 34,269 | $3,607,201 | -9% | 1.73% |
| 3. | Sivik Global Healthcare Krishen Sud | 30,000 | $3,158 | 0.92% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $88.25 | 2,833 | $249,999.98 | 2,933 | 2025-02-06 | Filing | |
| $88.50 | 15,000 | $1,327,500.00 | 16,000 | 2025-02-05 | Filing | |
| $113.68 | 3 | $341.04 | 20,599 | 2023-04-26 | Filing | |
| $105.47 | 136 | $14,343.92 | 20,631 | 2023-03-20 | Filing | |
| $109.20 | 11 | $1,201.20 | 20,495 | 2023-02-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $87.00 | 7,085 | $616,395.00 | 0 | 2025-11-10 | Filing | |
| $83.59 | 8,614 | $720,039.95 | 24,578 | 2025-11-03 | Filing | |
| $82.76 | 4,262 | $352,723.12 | 7,778 | 2025-04-25 | Filing | |
| $84.09 | 8,500 | $714,744.60 | 30,705 | 2025-02-19 | Filing | |
| $85.34 | 6,000 | $512,056.80 | 24,123 | 2025-02-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,573,821 | $1,115,009,425 | 0.96% | |
| 2. | 6,971,801 | $733,851,773 | 0.43% | |
| 3. | 4,651,002 | $489,564,471 | 0.76% | |
| 4. | 4,416,021 | $464,830,370 | 0.15% | |
| 5. | 2,497,975 | $262,936,848 | 0.37% |
News See All
Merck & Co., Inc. (MRK) and CEPI Launch Effort to Make Ebola Vaccine Cheaper and Easier to Distribute
Reuters reported that Merck & Co., Inc.
Dividend Contenders List: Top 20 Stocks
Dividend contenders are companies that have raised their dividends every year for at least a decade, but have not yet reached 25 straight years of growth.
Merck & Co (MRK) to Generate $70 Billion in Revenue from Emerging Businesses By Mid-2030s
With competition rising to the company’s cancer therapy Keytruda, Merck & Co., Inc. (NYSE:MRK) is setting itself up for long-term growth.
Broader Analyst Sentiment Bullish on Merck & Co. (MRK) Amid Tempered Short-Term Expectation and Long-Term Optimism
As of January 16, 2026, analyst sentiment on Merck & Co., Inc. (NYSE:MRK) stands broadly constructive, with roughly 60% of analysts bullish.
Merck (MRK) Builds Post-Keytruda Growth Plan, BMO Upgrades to Outperform
Merck & Co. Inc. (NYSE:MRK) ranks among the most active blue chip stocks to buy now. With a raised price target of $130 per share, BMO Capital Markets upgraded Merck & Co. Inc.
Merck & Co., Inc. (MRK) Poised for Breakout After Strategic M&A and Pipeline Expansion
TheFly reported on January 8 that Wolfe Research analyst Alexandria Hammond upgraded MRK to Outperform from Peer Perform with a $135 price target.
10 Undervalued Stocks to Invest in According to Goldman Sachs
Goldman Sachs released its 2026 Economic and Financial Market Outlook report on January 12, 2026, in which it reported that the economy is starting the new year with strong momentum and dismissed concerns...
10 Undervalued Wide Moat Stocks to Buy Right Now
As U.S. markets go further into 2026, they are witnessing a shift in the macro backdrop that is reshaping expectations across asset classes. Following a sluggish 2025, U.S.
Top 10 Oncology Stocks to Buy Now
The oncology market in the United States was estimated at $81.34 billion in 2025 and is expected to reach $211.78 billion by 2034 with a compound annual growth rate of 11.75%.